Fundraising FoxKALM Therapeutics
Huntsville, US · Founded 2024 · Delaware corporation
Find your way into KALM Therapeutics
Sign up to see every warm intro you have to KALM Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the KALM Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
CS
Chris SeibertExecutive
AS
Anuj SinghalCEO/Founder Kalm TherapeuticsAnuj Singhal is CEO and founder of KALM Therapeutics, which develops treatments for inflammatory diseases, and Drug Discovery Group Leader at CFD Research Corporation, with over 15 years of experience in drug discovery and development programs spanning immunology, oncology, infectious disease, and molecular biology.
Reported raises · per SEC filings
Form D private placements$590.4K disclosed across 1 round · 2024
▶$590.4KraisedAug 2024 · 14 investors · BiotechnologyRule 506(b)
▶$590.4KraisedAug 2024 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chris SeibertExecutive Officer, Director
- Anuj SinghalExecutive Officer, Director
- Offering amount
- $590.4K
- Amount sold
- $590.4K
- Minimum investment
- $25K
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has KALM Therapeutics raised?
- KALM Therapeutics has disclosed $590.4K raised across 1 round.
- Where is KALM Therapeutics headquartered?
- KALM Therapeutics is headquartered in Huntsville, US.